232 related articles for article (PubMed ID: 25770290)
21. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
22. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
23. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.
Huang S; Gulzar ZG; Salari K; Lapointe J; Brooks JD; Pollack JR
Oncogene; 2012 Sep; 31(37):4164-70. PubMed ID: 22179824
[TBL] [Abstract][Full Text] [Related]
24. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.
Liu W; Chang BL; Cramer S; Koty PP; Li T; Sun J; Turner AR; Von Kap-Herr C; Bobby P; Rao J; Zheng SL; Isaacs WB; Xu J
Clin Cancer Res; 2007 Sep; 13(17):5028-33. PubMed ID: 17785553
[TBL] [Abstract][Full Text] [Related]
25. N-cadherin switching occurs in high Gleason grade prostate cancer.
Jaggi M; Nazemi T; Abrahams NA; Baker JJ; Galich A; Smith LM; Balaji KC
Prostate; 2006 Feb; 66(2):193-9. PubMed ID: 16173043
[TBL] [Abstract][Full Text] [Related]
26. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
27. Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.
Yan J; Ojo D; Kapoor A; Lin X; Pinthus JH; Aziz T; Bismar TA; Wei F; Wong N; De Melo J; Cutz JC; Major P; Wood G; Peng H; Tang D
Cancer Res; 2016 Mar; 76(6):1603-14. PubMed ID: 26795349
[TBL] [Abstract][Full Text] [Related]
28. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
29. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
30. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
31. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
[TBL] [Abstract][Full Text] [Related]
32. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
33. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
34. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
35. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
37. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer.
Jarrard DF; Paul R; van Bokhoven A; Nguyen SH; Bova GS; Wheelock MJ; Johnson KR; Schalken J; Bussemakers M; Isaacs WB
Clin Cancer Res; 1997 Nov; 3(11):2121-8. PubMed ID: 9815605
[TBL] [Abstract][Full Text] [Related]
38. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
40. Establishing prostate cancer patient derived xenografts: lessons learned from older studies.
Russell PJ; Russell P; Rudduck C; Tse BW; Williams ED; Raghavan D
Prostate; 2015 May; 75(6):628-36. PubMed ID: 25560784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
